PMA device
Bard Flair Endovascular Stent Graft
Bard Peripheral Vascular · System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV, Class III) · First FDA decision Sep 4, 2009, newest May 18, 2010Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
1
Naming "Bard Flair"
MAUDE reports
0
Brand "Bard Flair", since 2015
PubMed studies
0
Mentioning "Bard Flair"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Bard Flair Endovascular Stent Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- BARD FLAIR ENDOVASCULAR STENT GRAFTPMA supplement
P060002-S006 · Decided May 18, 2010 · 230 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
- BARD FLAIR ENDOVASCULAR STENT GRAFTPMA supplement
P060002-S005 · Decided Sep 4, 2009 · 44 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Hemodialysis for Treatment of SchizophreniaNational determinationOn the books130.8Updated Dec 2, 2002
- Dialysis Access MaintenanceLocal determinationIn effectL34062CGS Administrators, LLCUpdated Feb 20, 2026
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
- Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower ExtremitiesLocal determinationIn effectL36377First Coast Service Options, Inc.Updated Nov 21, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Bard Flair", any status and sponsor, newest update first.
- Pivotal Study for the FLAIR Endovascular Stent GraftPivotal-lookingCompleted
C. R. BardPublic (BDX)
NCT00678249 · 227 participants · Start Jan 2001 · Primary completion Jun 2004
Device: FLAIR Endovascular Stent Graft; FLAIR Endovascular Stent Graft · For: Stenoses
Sites: New York, New York
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Bard Flair", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PFV
2,805 reports: 1,911 malfunction, 863 injury, 31 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0223-2016 · Started Oct 19, 2015 · Posted by FDA Nov 5, 2015
Reason given: Bard Peripheral Vascular (BPV) is recalling the Bard Flair Endovascular Stent Graft because of the harm associated with failure to deploy or deployment related issues that could occur during use.
Cause as FDA categorized it: Device Design · Device type: System, Endovascular Graft, Aortic Aneurysm Treatment (MIH)
Published research
The most relevant PubMed records for "Bard Flair"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PFV.
- GORE VIABAHN Endoprosthesis with Heparin Bioactive SurfaceW. L. Gore & Associates, Inc. · PMA 2022
- Covera Vascular Covered StentC.R. Bard, Inc. · PMA 2022
- WRAPSODY® Cell-Impermeable EndoprosthesisMerit Medical Systems, Inc. · PMA 2025
- Fluency Plus Endovascular Stent GraftBard Peripheral Vascular, Inc. · PMA 2017
- Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.